alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › updates

updates

3 studies tagged updates, dated 2019-11-08 to 2025-01-24. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist 2025-01-24
  2. Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia 2022-06-30
  3. Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions 2019-11-08

Studies

3 studies carry this tag.

Date range

2019 to 2025

Top journals

  • Journal of movement disorders 1
  • Journal of the Korean Society of Radiology 1
  • Molecular neurobiology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the Korean Society of Radiology 2025-01-24 Treatments

    Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea.

  2. Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Molecular neurobiology 2022-06-30 Genetics

    Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) primarily affect the motor and frontotemporal areas of the brain, respectively.

  3. Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of movement disorders 2019-11-08 Brain scans and imaging

    The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria.

All topic tags with their study counts